{
  "architectures": [
    "BertForSequenceClassification"
  ],
  "attention_probs_dropout_prob": 0.1,
  "classifier_dropout": null,
  "dtype": "float32",
  "hidden_act": "gelu",
  "hidden_dropout_prob": 0.1,
  "hidden_size": 768,
  "id2label": {
    "0": "Benign; No actionable therapy. [COSMIC]",
    "1": "Benign; No actionable therapy. [ClinVar]",
    "2": "Benign; No actionable therapy. [OncoKB]",
    "3": "Founder mutation; Genetic counseling required. [COSMIC]",
    "4": "Founder mutation; Genetic counseling required. [ClinVar]",
    "5": "Founder mutation; Genetic counseling required. [OncoKB]",
    "6": "Likely oncogenic; Chemo to moderate extent. [COSMIC]",
    "7": "Likely oncogenic; Chemo to moderate extent. [ClinVar]",
    "8": "Likely oncogenic; Chemo to moderate extent. [OncoKB]",
    "9": "Likely pathogenic; PARP inhibitors recommended. [COSMIC]",
    "10": "Likely pathogenic; PARP inhibitors recommended. [ClinVar]",
    "11": "Likely pathogenic; PARP inhibitors recommended. [OncoKB]",
    "12": "Oncogenic; TKI therapy (osimertinib). [COSMIC]",
    "13": "Oncogenic; TKI therapy (osimertinib). [ClinVar]",
    "14": "Oncogenic; TKI therapy (osimertinib). [OncoKB]",
    "15": "Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]",
    "16": "Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]",
    "17": "Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]",
    "18": "Pathogenic; Level 1 evidence for olaparib. [COSMIC]",
    "19": "Pathogenic; Level 1 evidence for olaparib. [ClinVar]",
    "20": "Pathogenic; Level 1 evidence for olaparib. [OncoKB]",
    "21": "Resistance mutation; Switch to alternative TKI. [COSMIC]",
    "22": "Resistance mutation; Switch to alternative TKI. [ClinVar]",
    "23": "Resistance mutation; Switch to alternative TKI. [OncoKB]",
    "24": "Truncating variant; Radiation not advised. [COSMIC]",
    "25": "Truncating variant; Radiation not advised. [ClinVar]",
    "26": "Truncating variant; Radiation not advised. [OncoKB]",
    "27": "VUS; Monitor and consider trials. [COSMIC]",
    "28": "VUS; Monitor and consider trials. [ClinVar]",
    "29": "VUS; Monitor and consider trials. [OncoKB]"
  },
  "initializer_range": 0.02,
  "intermediate_size": 3072,
  "label2id": {
    "Benign; No actionable therapy. [COSMIC]": 0,
    "Benign; No actionable therapy. [ClinVar]": 1,
    "Benign; No actionable therapy. [OncoKB]": 2,
    "Founder mutation; Genetic counseling required. [COSMIC]": 3,
    "Founder mutation; Genetic counseling required. [ClinVar]": 4,
    "Founder mutation; Genetic counseling required. [OncoKB]": 5,
    "Likely oncogenic; Chemo to moderate extent. [COSMIC]": 6,
    "Likely oncogenic; Chemo to moderate extent. [ClinVar]": 7,
    "Likely oncogenic; Chemo to moderate extent. [OncoKB]": 8,
    "Likely pathogenic; PARP inhibitors recommended. [COSMIC]": 9,
    "Likely pathogenic; PARP inhibitors recommended. [ClinVar]": 10,
    "Likely pathogenic; PARP inhibitors recommended. [OncoKB]": 11,
    "Oncogenic; TKI therapy (osimertinib). [COSMIC]": 12,
    "Oncogenic; TKI therapy (osimertinib). [ClinVar]": 13,
    "Oncogenic; TKI therapy (osimertinib). [OncoKB]": 14,
    "Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]": 15,
    "Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]": 16,
    "Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]": 17,
    "Pathogenic; Level 1 evidence for olaparib. [COSMIC]": 18,
    "Pathogenic; Level 1 evidence for olaparib. [ClinVar]": 19,
    "Pathogenic; Level 1 evidence for olaparib. [OncoKB]": 20,
    "Resistance mutation; Switch to alternative TKI. [COSMIC]": 21,
    "Resistance mutation; Switch to alternative TKI. [ClinVar]": 22,
    "Resistance mutation; Switch to alternative TKI. [OncoKB]": 23,
    "Truncating variant; Radiation not advised. [COSMIC]": 24,
    "Truncating variant; Radiation not advised. [ClinVar]": 25,
    "Truncating variant; Radiation not advised. [OncoKB]": 26,
    "VUS; Monitor and consider trials. [COSMIC]": 27,
    "VUS; Monitor and consider trials. [ClinVar]": 28,
    "VUS; Monitor and consider trials. [OncoKB]": 29
  },
  "layer_norm_eps": 1e-12,
  "max_position_embeddings": 512,
  "model_type": "bert",
  "num_attention_heads": 12,
  "num_hidden_layers": 12,
  "pad_token_id": 0,
  "position_embedding_type": "absolute",
  "problem_type": "single_label_classification",
  "transformers_version": "4.57.1",
  "type_vocab_size": 2,
  "use_cache": true,
  "vocab_size": 28996
}